Contact
searchSearch
HMP Global

Ankylosing Spondylitis

Featured Article

News
Opioid Use Associated With Fractures in People With Ankylosing Spondylitis
12/20/2023
Lisa Kuhns, PhD, MD
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical...
12/20/2023
First Report Managed Care
News
Analysis Finds Similar Safety Profile with Upadacitinib Across Conditions
11/03/2023
Jolynn Tumolo
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor...
11/03/2023
First Report Managed Care
News
High Rates of Depression, Anxiety in Patients With Ankylosing Spondylitis
10/06/2023
Jolynn Tumolo
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing...
10/06/2023
First Report Managed Care
News
Achieving Disease Control in PsA, AS Associated with Lower Medical Costs
09/15/2023
Jolynn Tumolo
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in...
09/15/2023
First Report Managed Care
News
Can Tumor Necrosis Factor Inhibitors Reduce the Risk of Fractures in AS Patients?
08/30/2023
Danielle Sposato
Researchers sought to understand if fracture risk decreased among individuals with ankylosing spondylitis with tumor necrosis factor inhibitors treatments compared to non-AS patients.
Researchers sought to understand if fracture risk decreased among individuals with ankylosing spondylitis with tumor necrosis factor inhibitors treatments compared to non-AS patients.
Researchers sought to understand...
08/30/2023
First Report Managed Care
News
Fear of Movement in Patients With Ankylosing Spondylitis Linked With Lower Life Quality
07/27/2023
Jolynn Tumolo
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a...
07/27/2023
First Report Managed Care
News
Tildrakizumab No Better Than Placebo for Ankylosing Spondylitis
06/09/2023
Jolynn Tumolo
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab...
06/09/2023
First Report Managed Care
News
Risk of Psychiatric Comorbidity Higher in Patients With Ankylosing Spondylitis
05/19/2023
Jolynn Tumolo
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a...
05/19/2023
First Report Managed Care
News
Short-term Biosimilar Adalimumab Provides Long-term Relief for Ankylosing Spondylitis
04/14/2023
Jolynn Tumolo
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar...
04/14/2023
First Report Managed Care
News
JAK Inhibitor Improves Slate of Patient-Reported Outcomes in Biologic Refractory Ankylosing Spondylitis
03/28/2023
Jolynn Tumolo
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK...
03/28/2023
First Report Managed Care
News
Baseline Variables Predict Probability of Initial Response to TNFi Inhibitors in Patients With AS
10/27/2022
Edan Stanley
Researchers sought to develop models of the probability of short-term response to tumor necrosis factor inhibitor treatment in patients with ankylosing spondylitis.
Researchers sought to develop models of the probability of short-term response to tumor necrosis factor inhibitor treatment in patients with ankylosing spondylitis.
Researchers sought to develop...
10/27/2022
First Report Managed Care

Newsfeed

News
Opioid Use Associated With Fractures in People With Ankylosing Spondylitis
12/20/2023
Lisa Kuhns, PhD, MD
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical...
12/20/2023
First Report Managed Care
News
Analysis Finds Similar Safety Profile with Upadacitinib Across Conditions
11/03/2023
Jolynn Tumolo
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor...
11/03/2023
First Report Managed Care
News
High Rates of Depression, Anxiety in Patients With Ankylosing Spondylitis
10/06/2023
Jolynn Tumolo
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing...
10/06/2023
First Report Managed Care
News
Achieving Disease Control in PsA, AS Associated with Lower Medical Costs
09/15/2023
Jolynn Tumolo
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in...
09/15/2023
First Report Managed Care
News
Can Tumor Necrosis Factor Inhibitors Reduce the Risk of Fractures in AS Patients?
08/30/2023
Danielle Sposato
Researchers sought to understand if fracture risk decreased among individuals with ankylosing spondylitis with tumor necrosis factor inhibitors treatments compared to non-AS patients.
Researchers sought to understand if fracture risk decreased among individuals with ankylosing spondylitis with tumor necrosis factor inhibitors treatments compared to non-AS patients.
Researchers sought to understand...
08/30/2023
First Report Managed Care
News
Fear of Movement in Patients With Ankylosing Spondylitis Linked With Lower Life Quality
07/27/2023
Jolynn Tumolo
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a...
07/27/2023
First Report Managed Care
News
Tildrakizumab No Better Than Placebo for Ankylosing Spondylitis
06/09/2023
Jolynn Tumolo
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab...
06/09/2023
First Report Managed Care
News
Risk of Psychiatric Comorbidity Higher in Patients With Ankylosing Spondylitis
05/19/2023
Jolynn Tumolo
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a...
05/19/2023
First Report Managed Care
News
Short-term Biosimilar Adalimumab Provides Long-term Relief for Ankylosing Spondylitis
04/14/2023
Jolynn Tumolo
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar...
04/14/2023
First Report Managed Care
News
JAK Inhibitor Improves Slate of Patient-Reported Outcomes in Biologic Refractory Ankylosing Spondylitis
03/28/2023
Jolynn Tumolo
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK...
03/28/2023
First Report Managed Care
News
Pharmacist-Led Outreach Boosts SGLT2 Inhibitor Initiation in Veterans With CKD and Diabetes
06/05/2026
Grace Taylor, MS, MA
Clinical pharmacists nearly doubled SGLT2 inhibitor initiation among veterans with chronic kidney disease (CKD) and type 2 diabetes in a large US Department of Veterans Affairs quality improvement study.
Clinical pharmacists nearly doubled SGLT2 inhibitor initiation among veterans with chronic kidney disease (CKD) and type 2 diabetes in a large US Department of Veterans Affairs quality improvement study.
Clinical pharmacists nearly...
06/05/2026
First Report Managed Care
News
Reducing Reliance on Epidural Steroid Injections Through Evidence-Based De-Implementation
06/05/2026
Rebecca Amrick
Researchers examined epidural spinal injections as a candidate for de-implementation, specifically for patients with chronic low back pain, and provided suggestions for successfully redirecting care toward more effective and sustainable...
Researchers examined epidural spinal injections as a candidate for de-implementation, specifically for patients with chronic low back pain, and provided suggestions for successfully redirecting care toward more effective and sustainable...
Researchers examined epidural...
06/05/2026
First Report Managed Care
News
CT-P39 Shows Promise as a Cost-Saving Alternative to Omalizumab for CSU
06/04/2026
Rebecca Amrick
A clinical trial comparing CT-P39 with reference omalizumab found both drugs to be comparable both in efficacy and safety, indicating CT-P39 as a suitable alternative to omalizumab for patients with chronic spontaneous urticaria (CSU).
A clinical trial comparing CT-P39 with reference omalizumab found both drugs to be comparable both in efficacy and safety, indicating CT-P39 as a suitable alternative to omalizumab for patients with chronic spontaneous urticaria (CSU).
A clinical trial comparing...
06/04/2026
First Report Managed Care
Behind the Bill
CMS Finalizes Federal IDR Rule to Streamline No Surprises Act Dispute Resolution
05/29/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has finalized updates to the federal Independent Dispute Resolution (IDR) process under the No Surprises Act, lowering administrative fees, creating a centralized dispute portal, and...
The Centers for Medicare & Medicaid Services (CMS) has finalized updates to the federal Independent Dispute Resolution (IDR) process under the No Surprises Act, lowering administrative fees, creating a centralized dispute portal, and...
The Centers for Medicare &...
05/29/2026
First Report Managed Care
News
Differences in OUD Treatment Coverage Across Medicaid Managed Care Plans From 2015 to 2019
05/26/2026
Rebecca Amrick
From 2015 to 2019, Medicaid coverage of opioid use disorder (OUD) increased while plans covering treatment services decreased, raising concerns about substance use care plans and treating patients with addiction.
From 2015 to 2019, Medicaid coverage of opioid use disorder (OUD) increased while plans covering treatment services decreased, raising concerns about substance use care plans and treating patients with addiction.
From 2015 to 2019, Medicaid...
05/26/2026
First Report Managed Care
News
Linvoseltamab Demonstrates Lower Care Costs than Teclistamab and Elranatamab for TCE RRMM
05/26/2026
Rebecca Amrick
Linvoseltamab demonstrates lower and comparable care costs compared to teclistamab and elranatamab, appearing as a possible lower-cost alternative for treating patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma...
Linvoseltamab demonstrates lower and comparable care costs compared to teclistamab and elranatamab, appearing as a possible lower-cost alternative for treating patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma...
Linvoseltamab demonstrates lower...
05/26/2026
First Report Managed Care
News
Comorbidities Increase Clinical and Economic Burden for Patients With Chronic Kidney Disease
05/22/2026
Rebecca Amrick
The clinical and economic burden of chronic kidney disease (CKD) is increased when combined with comorbidities such as type 2 diabetes and heart failure, highlighting the need for improved policies and procedures to optimize disease...
The clinical and economic burden of chronic kidney disease (CKD) is increased when combined with comorbidities such as type 2 diabetes and heart failure, highlighting the need for improved policies and procedures to optimize disease...
The clinical and economic burden...
05/22/2026
First Report Managed Care
News
Pembrolizumab Plus Chemotherapy Improves Survival in mNSCLC at Higher Cost
05/22/2026
Rebecca Amrick
Pembrolizumab plus chemotherapy demonstrates more clinical efficiency in treating patients with metastatic non–small cell lung cancer (mNSCLC), but prolonged survival leads to higher overall health care costs.
Pembrolizumab plus chemotherapy demonstrates more clinical efficiency in treating patients with metastatic non–small cell lung cancer (mNSCLC), but prolonged survival leads to higher overall health care costs.
Pembrolizumab plus chemotherapy...
05/22/2026
First Report Managed Care
Behind the Bill
Congress Targets Enforcement Gaps in the No Surprises Act
05/22/2026
Hannah Musick
A bipartisan bill aims to strengthen enforcement of the No Surprises Act amid growing concerns that some health plans are failing to comply with binding payment decisions in the federal dispute resolution process.
A bipartisan bill aims to strengthen enforcement of the No Surprises Act amid growing concerns that some health plans are failing to comply with binding payment decisions in the federal dispute resolution process.
A bipartisan bill aims to...
05/22/2026
First Report Managed Care
News
Asciminib Shows Durable Frontline Benefit in Newly Diagnosed CML
05/20/2026
Hannah Musick
At 96 weeks, asciminib demonstrated higher major molecular response rates and fewer treatment discontinuations due to adverse events compared with imatinib and second-generation tyrosine kinase inhibitors in newly diagnosed chronic myeloid...
At 96 weeks, asciminib demonstrated higher major molecular response rates and fewer treatment discontinuations due to adverse events compared with imatinib and second-generation tyrosine kinase inhibitors in newly diagnosed chronic myeloid...
At 96 weeks, asciminib...
05/20/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use